Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.60 |
| ▸ | CTSL | P07711 | 13/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 9/20 | 0.48 |
| ▸ | CTSV | O60911 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744609 | 0.93 | CTSK (0.70) | CTSKCTSLCTSBTAS1R3TAS1R1 | |
| SCHEMBL5762282 | 0.86 | CTSK (0.54) | CTSKCTSLCTSBTAS1R3TAS1R1 | |
| SCHEMBL5744937 | 0.80 | TAS1R3 (0.64) | CTSKCTSLCTSBTAS1R3TAS1R1 | |
| SCHEMBL5743287 | 0.76 | CTSK (0.69) | CTSKCTSLCTSBCTSS | |
| SCHEMBL5741731 | 0.76 | CTSK (0.70) | CTSKCTSBTAS1R3TAS1R1CTSS | |
| SCHEMBL5742161 | 0.74 | CASP1 (0.62) | CTSKCTSLCTSBCTSS | |
| SCHEMBL6476716 | 0.74 | CTSK (0.48) | CTSKCTSLCTSBCTSS | |
| SCHEMBL5744346 | 0.74 | TAS1R3 (0.50) | CTSKCTSLTAS1R3TAS1R1CTSS | |
| SCHEMBL5743949 | 0.73 | CTSK (0.57) | CTSKCTSLCTSBTAS1R3TAS1R1 | |
| SCHEMBL6485072 | 0.73 | CTSK (0.55) | CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | CTSK 4/4885CTSL 10/4885CTSB 12/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | CTSK 5/4885CTSL 13/4885CTSB 12/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | CTSK 3/4885CTSL 9/4885CTSB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.